Newer anticonvulsants in the treatment of anxiety disorders
Referencias
Additional references
Alderson P, Green S, Higgins JP. Assessment of study quality. In: Alderson P, Green S, Higgins JPT editor(s). Cochrane Reviewers’ Handbook 4.2.1 (updated December) Section 8. Chichester, UK: John Wiley & Sons, Ltd., 2004.
Als‐Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials ‐ A reflection of treatment effect or adverse events?. JAMA 2003;290:921‐8.
Anand A, Bukhari L, Jennings SA, Lee C, Kamat M, Shekhar A, et al. A preliminary open‐label study of zonisamide treatment for bipolar depression in 10 patients. Journal of Clinical Psychiatry 2005;66(2):195‐8.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐III). 3rd Edition. Washington, DC: American Psychiatric Association, 1980.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM‐IV). 4th Edition. Washington, DC: American Psychiatric Association, 1994.
Ashton H, Young AH. GABA‐ergic drugs: exit stage left, enter stage right. Journal of Psychopharmacology 2003;17(2):174‐8.
Baker CB, Johnsrud MT, Crismon ML, Rosenheck RA, Woods SW. Quantitative analysis of sponsorship bias in economic studies of antidepressants. British Journal of Psychiatry 2003;183:498‐506.
Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al. Evidence‐based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 2005;19(6):567‐96.
Bandelow B, Ruther E. Treatment‐resistant panic disorder. CNS Spectrums 2004;9(10):725‐39.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961;4:561‐71.
Berigan TR. Zonisamide treatment of bipolar disorder: a case report. Canadian Journal of Psychiatry 2002;47(9):887.
Berigan T. Oxcarbazepine treatment of posttraumatic stress disorder. Canadian Journal of Psychiatry 2002;47(10):973‐4.
Berigan T. Treatment of posttraumatic stress disorder with tiagabine. Canadian Journal of Psychiatry 2002;47(8):788.
Berlant JL. Topiramate in posttraumatic stress disorder: Preliminary clinical observations. Journal of Clinical Psychiatry 2001;62 Suppl 17:60‐3.
Berlant JL. Prospective open‐label study of add‐on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry 2004;4(1):24.
Besag FM. Behavioural effects of the new anticonvulsants. Drug Safety 2001;24(7):513‐36.
Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Research 2002;51:31‐71.
Blake DD, Weathers FW, Nagy LM, et al. A clinician rating scale for assessing current and lifetime PTSD: The CAPS‐1. Behavior Therapy 1990;21:187‐8.
Borowicz KK, Piskorska B, Kimber‐Trojnar Z, Malek R, Sobieszek G, Czuczwar SJ. Is there any future for felbamate treatment?. Polish Journal of Pharmacology 2004;56(3):289‐94.
Boylan LS, Devinsky O, Barry JJ, Ketter TA. Psychiatric uses of antiepileptic treatments. Epilepsy and Behavior 2002;3:S54‐S59.
Brunbech L, Sabers A. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: A comparative review of newer versus older agents. Drugs 2002;62(4):593‐604.
Crane D. Tiagabine for the treatment of anxiety. Depression and Anxiety 2003;18:51‐2.
Crawford P. An audit of topiramite use in a general neurology clinic. Seizure 1998;7:207‐11.
Damsa C, Warczyk S, Cailhol L, Kelley‐Puskas AM, Cicotti A, Lazignac C, et al. Panic attacks associated with topiramate. Journal of Clinical Psychiatry 2006;67(2):326‐7.
Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis.. In: Egger M, Davey SG, Altman DG editor(s). Systematic Reviews in Health Care: Meta‐Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001.
Deeks JJ. Issues in the selection of a summary statistic for meta‐analysis of clinical trials with binary outcomes. Statistics in Medicine 2002;21(11):1575‐600.
Deeks J, Higgins J, Altman D. Cochrane Reviewers’ Handbook 4.2.1 (updated December 2003). In: Alderson P, Green S, Higgins J editor(s). The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd., 2003.
Dickersin K, Min YI, Meinert CL. Factors influencing the publication of research results : follow‐up of applications submitted to two substantial review boards. JAMA 1992;267(3):374‐8.
Eaterbrook PJ, Berline JA, Gopaian R, Matthews DR. Publication bias in clinical research. Lancet 1991;337(8746):867‐72.
Egger M. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315:629‐34.
Elbourne ER, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta‐analyses involving cross‐over trials: Methodological issues. International Journal of Epidemiology 2002;31:140‐9.
Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, et al. A randomized, double‐blind, placebo‐controlled, fixed‐dose, multi‐center study of pregabalin in patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology 2003;23(3):240‐9.
French JA, Kanner AM, Bautista J, Abou‐Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy. Neurology 2004;62:1252‐60.
Ghislain P, Roujeau J. Treatment of severe drug reactions: Stevens‐Johnson Syndrome, Toxic Epidermal Necrolysis and Hypersensitivity syndrome. Dermatology Online Journal2002; Vol. 8, issue 1.
Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, et al. The Economic Burden of Anxiety Disorders in the 1990s. Journal of Clinical Psychiatry 1999;60(7):427‐35.
Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: U.S. National Institute of Health, 1976.
Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32:50‐5.
Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry 1960;23:56‐62.
Hertzberg MA, Butterfield MI, Feldman ME, Beckham JC, Sutherland SM, Connor KM, et al. A preliminary study of lamatrogine for the treatment of postraumatic stress disorder. Biological Psychiatry 1999;45(9):1226‐9.
Higgins JTP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(6):557‐60.
Kalviainen R, Nousiainen I, Mantyjarvi M, Nikoskelainen E, Partanen J, Partanen K, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999;53:922‐6.
Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age‐of‐onset distributions of DSM‐IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005;62(2):593‐602.
Ketter TA, Post RM, Theodore WH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999;53 Suppl 2:S53‐S67.
Kinrys G, Wygant LE, Pardo TB, Melo M. Levetiracetam for treatment‐refractory posttraumatic stress disorder. Journal of Clinical Psychiatry 2006;67(2):211‐4.
Kober D, Gabbard GO. Topiramate‐induced psychosis. American Journal of Psychiatry 2005;162(8):1542.
Lamberty Y, Falter U, Gower AJ, Klitgaard H. Anxiolytic profile of the antiepileptic drug levetiracetam in the Vogel conflict test in the rat. European Journal of Pharmacology 2003;469:97‐102.
LaRoche SM, Helmers SL. The new antiepileptic drugs: Scientific review. JAMA 2004;291(5):605‐14.
Law J, Garrett Z, Nye C. Speech and language therapy interventions for children with primary speech and language delay or disorder. Cochrane Database of Systematic Reviews 2003, Issue 3.
Leppik IE. Zonisamide: Chemistry, mechanism of action, and pharmacokinetics. Seizure 2004;13S:S5‐S9.
Liebowitz MR. Social Phobia. Modern Problems in Pharmacopsychiatry 1987;22:141‐73.
McLean M. Gabapentin. In: Wylie E editor(s). The Treatment of Epilepsy. 3rd Edition. Philadelphia, PA: Lippincot Williams & Wilkins, 2001:915‐932.
Mirza NR, Bright JL, Stanhope KJ, Wyatt A, Harrington NR. Lamotrigine has an anxiolytic‐like profile in the rat conditioned emotional response test of anxiety: a potential role for sodium channels?. Psychopharmacology 2005;180(1):159‐68.
Moncrieff J, Churchill R, Drummond DC, McGuire H. Development of a quality assessment instrument for trials of treatments for depression and neurosis. International Journal of Methods in Psychiatric Research 2001;10(3):126‐33.
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382‐9.
Ozkara C, Ozmen M, Erdogan A, Yalug I. Topiramate related obsessive‐compulsive disorder. European Psychiatry 2005;20(1):78‐9.
Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, et al. Treatment non‐response in OCD: methodological and operational definitions. International Journal of Neuropsychopharmacology 2002;5:181‐91.
Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder. Journal of Clinical Psychopharmacology 2004;24(2):141‐9.
Pollack MH, Matthews, M, Scott EL. Gabapentin as a Potential Treatment for Anxiety Disorders. American Journal of Psychiatry 1998;155:992‐3.
Post RM, Chalecka‐Franaszek E, Hough CJ. Mechanisms of action of anticonvulsants and new mood stablizers. In: JC Soares, S Gershon editor(s). Handbook of Medical Psychiatry. New York, NY: Marcel Dekker, Inc., 2003:767‐791.
R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing, 2005. [ISBN 3‐900051‐07‐0]
Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, et al. Pregabalin for treatment of generalized anxiety disorder: a 4‐week, multicenter, double‐blind, placebo‐controlled trial of pregabalin and alprazolam. Archives of General Psychiatry 2005;62(9):1022‐30.
Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. International Journal of Epidemiology 2002;31:150‐3.
Scherer RW, Dickersin K, Langenberg P. Full publication of results initially presented in abstracts. A meta‐analysis. JAMA 1994;272(2):158‐62.
Schwartz TL, Azhar N, Husain J, Nihalani N, Simionescu M, Coovert D, et al. An open‐label study of tiagabine as augmentation therapy for anxiety. Annals of Clinical Psychiatry 2005;17(3):167‐72.
Sheehan DV, Harnett‐Sheehan K, Raj BA. The measurement of disability. International Clinical Psychopharmacology 1996;11 Suppl 3:89‐95.
Smith D, Chadwick D, Baker G, Davis G, Dewey M. Seizure severity and the quality of life. Epilepsia 1993;34 Suppl 5:S31‐35.
Spitzer R, Williams J, Gibbons M. Instructional manual for the structured clinical interview for DSM‐IV. New York, NY: New York State Psychiatric Institute, 1996.
Taylor FB. Tiagabine for posttraumatic stress disorder: a case series of 7 women. Journal of Clinical Psychiatry 2003;64(12):1421‐5.
Thompson SG. Why sources of heterogeneity in meta‐analysis should be investigated. BMJ 1994;309(6965):1351‐5.
Van Ameringen M, Mancini C, Pipe B, Bennett M. Antiepileptic drugs in the treatment of anxiety disorders. Drugs 2004;64(19):2199‐220.
Van Ameringen M, Mancini C, Pipe B, Oakman J, Bennett M. An open trial of topiramate in the treatment of generalized social phobia. Journal of Clinical Psychiatry 2004;65(12):1647‐8.
Verbeke M, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York, NY: Springer, 2000.
World Health Organisation. The ICD‐9 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organisation, 1975.
World Health Organisation. The ICD‐10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva, Switzerland: World Health Organisation, 1992.
Zhang W, Connor KM, Davidson JR. Levetiracetam in social phobia: a placebo controlled pilot study. Journal of Psychopharmacology 2005;19(5):551‐3.
Zwannger P, Baghai TC, Schule C, Minov C, Padberg F, Moller H, et al. Tiagabine improves panic and agoraphobia in panic disorder patients. Journal of Clinical Psychiatry 2001;62(8):656‐7.
Zwanzger P, Baghai TC, Schuele C, Strohle A, Padberg F, Kathmann N, et al. Vigabatrin decreases cholecystokinin‐tetrapeptide (CCK‐4) induced panic in healthy volunteers. Neuropsychopharmacology 2001;25(5):699‐703.
Zwanzger P, Eser D, Padberg F, Baghai TC, Schule C, Rotzer F, et al. Effects of tiagabine on cholecystokinin‐tetrapeptide (CCK‐4)‐induced anxiety in healthy volunteers. Depression and Anxiety 2003;18(3):140‐3.
